Top-level science through the eyes of an expert.
The eighth Webinar.
The next episode of the Genoskin Webinar series is now scheduled on October 17, 2024 at 8 a.m. (PST), 11 a.m. (EST), 5 p.m. (CET). The webinar is open to English-speaking participants with a solid scientific background. Featured speaker is Dr. Manon Scholaert, Scientist at Genoskin.
In this webinar, Dr. Manon Scholaert will walk us through her cutting-edge research that utilizes advanced bioengineering techniques to study the interactions of immune cells in ex vivo human skin
The field of drug development is witnessing a remarkable surge in the development of innovative strategies. There is a need to develop technological platforms capable of generating human data prior to progressing to clinical trials.
In this webinar, we introduce a new, flexible solution designed for the comprehensive monitoring of the human skin ecosystem’s response to immunogenic drugs over time. This solution, based on unique bioengineering techniques that preserve surgical resections in a long survival state, allows for the first time a comprehensive analysis of resident immune cells response at both organ and single-cell levels. Using the mRNA-1273 COVID-19 vaccine as a case study, we will demonstrate how our platform characterizes the sequential molecular events triggered upon detection of the exogenous substance.
Our findings highlight that the vaccine consistently targets DC/macrophages and mast cells, regardless of the administration route, while promoting specific cell–cell communications in surrounding immune cell subsets. Given its direct translational relevance, this approach provides a multiscale vision of genuine human tissue immunity that could pave the way toward the development of new vaccination and drug development strategies.
About the speaker:
Dr. Manon Scholaert
Scientist at Genoskin, Toulouse, France.After obtaining an engineering degree in Biology from INSA Toulouse, Dr. Manon Scholaert pursued a CIFRE PhD in partnership with the Toulouse Institute of Infectious and Inflammatory Diseases (INFINITY) and Genoskin from 2020 to 2023. Her research focused on developing the MANTIS method, a multiplex imaging technique for studying immune cells in the skin, and investigating immune responses in the ex vivo skin model HypoSkin® after mRNA COVID-19 vaccine injections. In October 2023, she joined Genoskin’s Research and Development team as a Scientist. Her current work involves further development of multiplex imaging techniques and research on the VaxSkin® platform, which focuses on studying cutaneous immune responses to vaccines.
Comments are closed.